Tag:
IMS Health
Latest Headlines
Latest Headlines
IMS continues cloud deal blitz with 360 Vantage buy
IMS Health has made its third cloud-based acquisition in as many months, snapping up mobile sales and marketing systems provider 360 Vantage. The deal continues IMS' whirlwind push into the cloud that has also seen it snag Appature and Semantelli in the past few months.
IMS Health acquires social media analytics startup Semantelli
IMS Health has purchased Semantelli, a software startup whose technology reduces the risk of social media engagement for pharma companies. Drugmakers have tiptoed in the wild realm of the social web over fears about regulatory snafus and compliance headaches. Semantelli has helped pharma companies with those worries and has been rewarded.
Generics dampen US drug spending; payers fear rising specialty costs
It's confirmed: Another study shows that U.S. drug spending dropped ever so slightly last year. The obvious culprit is generic drugs, with major blockbusters such as Pfizer's ($PFE) Lipitor and AstraZeneca's ($AZN) Seroquel IR now facing cheap rivals.
Pfizer's popular 'Z-Pak' carries increased fatal risk for some, FDA says
Doctors prescribe the "Z-Pak" for everything from ear infections to pneumonia. But the FDA wants to make clear that for a small group of people, there is a better than average chance it will mess with their heart rhythms and possibly kill them.
Does $1B really make a blockbuster anymore?
When is a blockbuster not a blockbuster? When its sales are adjusted for inflation--or for share of the global pharma market. That $1 billion blockbuster threshold might have been a lofty goal in 1987, but in today's dollars, the bar would stand at $1.75 billion, an IMS Health consultant postulates in an article for PharmaPhorum .
Brain scans may help docs target which antipsychotics work
One of the hot trends in cancer medication is genetic tests that can tell doctors if a related treatment will work on certain patients.
Sanofi, Otsuka amp up their Turkish ambitions
Turkey's pharma market isn't as high-profile as the oft-celebrated China or India. But that doesn't mean foreign drugmakers aren't looking for ways to beef up their operations in the country.
China may not produce for Big Pharma long-term
Benjamin Shobert, founder and managing director of consultancy Rubicon Strategy Group, says there are significant looming questions about whether the Chinese market will pay off in the long run for Big Pharma.
IMS Health buys trial-enrollment software startup
IMS Health has gobbled up DecisionView, a San Francisco-based provider of web-based software that analyzes patient enrollment in clinical trials via an acquisition.
Generics deals drive increase in pharma M&A
Pharma M&A activity is heating up, particularly among medium-sized companies, and shows signs of accelerating further, MarketWatch reports.
